Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

Therapy with Skyrizi is 600mg given by infusion at weeks zero, four and eight, followed by a 360mg subcutaneous shot given at week 12 and every eight weeks thereafter. The FDA is also reviewing a ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi benefitted from an additional 12 weeks of treatment, according to study ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel ...